LONDRES.-An Oxford University study found that the number of people suffering from severe cerebral palsy with a vaccine against coronavirus is approximately the same as those received by Pfizer and Modern, which were vaccinated with Astra.
According to the study, 4 out of every 1 million people experienced cerebral venous thrombosis (TVC) were able to receive the Pfizer or Modern vaccine, in front of 5 out of 1 million people with the AstraZeneca vaccine.
The risk of contraindication TVC is much mayor for those who contraen Covid-19 (39 in a million patients) than for those who are evacuated.
The use of AstraZeneca’s vaccine has been limited to many countries and has led to problems with blood clots.
The risk of cerebral arterial thrombosis, which has caused many regulators to discontinue or discontinue the use of AstraZeneca and J&J vaccines, appears to be very similar for the AstraZeneca vaccine (5 out of a million) as for Pfizer and Moderna’s mRNA. vaccines (4 out of a million). pic.twitter.com/KZcMCIQVXd
– Sputnik V (@sputnikvaccine)
16 April 2021
The comparison of the TVC notified cases in patients with Covid-19 in comparison with the TVC cases in those who received a Covid-19 vaccine:
In this study of more than 500 million patients with Covid-19, the TVC won 39 of every one million patients.
In more than 480 million people who receive an ARNm vaccine against Covid-19 (Pfizer or Modern), TVC produces 4 in a million.
It has been reported that the TVC will estimate approximately 5 out of every 1 million people disposed of the first dose of the AstraZeneca vaccine.
Compared to the vacancies of ARNm, the risk of a TVC by Covid-19 is approximately 10 times mayor.
Compared to the AstraZeneca vacancy, the risk of a TVC by Covid-19 is approximately 8 times mayor.
However, it should be noted that all comparisons should be interpreted with caution and that the data are currently being analyzed.
In closing:
TVC’s Sufferer’s risk of AstraZeneca’s first dose is 5 million in vacancies; it has a cerebral venous thrombosis after a Pfizer or Modern vaccine is 4 million; to suffer this rare thrombus in patients with covid, 39 of each million. For the study, there were 513,284 coronavirus-infected patients and 489,871 with one ARN message (Pfizer or Moderna). The dates of the AstraZeneca risk are described by the EMA.